Nature of regulatory T cells in the context of allergic disease

Allergy, Asthma and Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 106-110

  Ozdemir, Cevdet ^a   Akdis, Mübeccel ^b   Akdis, Cezmi A ^b  

^a Division of Pediatric Allergy and Immunology   (Turkey)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Allergen specific immunotherapy; Dendritic cells; Mucosal tolerance; Regulatory T cells

Indexed keywords

ALLERGEN; FC EPSILON RECEPTOR I; FC EPSILON RECEPTOR II; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC RHINITIS; ALLERGY; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DESENSITIZATION; DISEASE COURSE; EOSINOPHIL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; MACROPHAGE; MAST CELL; MONOCYTE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 51349120557     PISSN: 17101484     EISSN: None     Source Type: Journal    
DOI: 10.2310/7480.2008.00015     Document Type: Article

References (46)

1. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;119:780-91.
2. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113:395-400.
3. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761-71.
4. Marcotte GV, Braun CM, Norman PS, et al. Effects of peptide therapy on ex vivo T cell responses. J Allergy Clin Immunol 1998; 101:506-13.
5. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am 2005;25:283-99.
6. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 2006; 61:796-807.
7. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936.
8. Frew AJ. How does sublingual immunotherapy work? J Allergy Clin Immunol 2007;120:533-6.
9. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4-12.
10. Kussebi F, Karamloo F, Akdis M, et al. Advances in immunological treatment of allergy. Curr Med Chem 2003;2:297-308.
11. Bahceciler NN, Ozdemir C, Barlan IB. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr Med Chem 2007;14:265-9.
12. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-5.
13. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999;341: 468-75.
14. Ozdemir C, Yazi D, Gocmen I, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18:508-15.
15. Larché M. Regulatory T cells in allergy and asthma. Chest 2007; 132:1007-14.
16. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13.
17. Larché M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006;18:745-50.
18. Hawrylowicz CM, O'Garra A. Potential role of IL-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005;5. 271-83.
19. Jutel M, Müller UR, Fricker M, et al. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996;26:1112-8.
20. Plewako H, Wosinska K, Arvidsson M, et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006;141:346-53.
21. Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995;25:704-12.
22. Plewako H, Arvidsson M, Oancea I, et al. The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy 2004;34:1862-7.
23. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
24. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-65.
25. Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001;31: 1705-13.
26. Rak S, Heinrich C, Jacobsen L, et al. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Chn Immunol 2001;108: 921-8.
27. Durham SR, Varney MA, Gaga M, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999;29:1490-6.
28. Shim JY, Kim BS, Cho SH, et al. Allergen-specific conventional immunotherapy decreases immunoglobulin E mediated basophil histamine releasability. Clin Exp Allergy 2003;33:52-7.
29. Marogna. M, Spadolini I, Massolo A, et al, J Allergy Clin Immunol 2005;115:1184-8.
30. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001;193:51-60.
31. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dcndritic cells. J Exp Med 2000;192:1213-22.
32. De Heer HJ, Hammad H, Soullié T, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004;200:89-98.
33. Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003;112:141-8.
34. Van Wilsem EJ, Van Hoogstraten IM, Brevé J, et al. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994;83:128-32.
35. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-40.
36. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
37. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33: 1205-14.
38. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
39. Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006;18:738-44.
40. Mantel PY, Kuipers H, Boyman O, et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5(12):e329.
41. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003;132:13-24.
42. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313-8.
43. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-208.
44. Visco V, Dolecek V, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157:956-62.
45. Flicker S, Steinberger P, Norderhaug L, et al. Conversion of grass pollen allergen specific human IgE into a protective IgG1 antibody. Eur J Immunol 2002;32:2156-62.
46. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.